Show results for
Refine by
Oncology Software In France
19 software items found
by:Intrasense based inMontpellier, FRANCE
Myrian® XP-Prostate is an application dedicated to the visualization and analysis of prostate magnetic resonance ...
by:Intrasense based inMontpellier, FRANCE
Myrian® XP-Colon workstation is used to visualize CT Colonography (CTC) images - prone and supine acquisitions - in both 2D and 3D modes. This workstation provides a range of features and tools dedicated to colon exploration, report generation and DICOM ...
by:Intrasense based inMontpellier, FRANCE
Myrian® XP-Liver is an application dedicated to the visualization and analysis of injected liver ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Sensitive novel fusion detection optimized for small lung cancer FFPE biopsies enhance patient care. SOPHiA DDM™ Dx RNAtarget Oncology Solution (ROS) is a CE-marked in vitro diagnostic (IVD) application based on next-generation sequencing (NGS) enabling accurate and sensitive detection of novel (partner-agnostic) fusions and exon skipping events, even with minimal RNA ...
by:Intrasense based inMontpellier, FRANCE
Myrian® XP-Abdofat is a non-invasive post processing application dedicated to the automatic segmentation and quantification of the abdominal ...
by:Intrasense based inMontpellier, FRANCE
The Myrian® XP-Oncology module is designed for longitudinal follow-up of diagnosed tumor lesions. ...
by:Olea Medical based inLa Ciotat, FRANCE
Our advanced oncology MRI imaging software solution provides a better understanding of the pathology and improves communication across the different medical specialties for better patient care. ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Genomic profiling is driving precision oncology. From targeted to comprehensive solutions, Next-Generation-Sequencing (NGS) offers the capacity to simultaneously analyze a select set of genes, regions, and biomarkers based on known involvement across solid tumor such as lung, colon, breast, melanoma, gastric, and ovarian cancers. ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Hematological tumors represent the fourth most frequent cancer type in the developed world. In addition to the continuously evolving clinical guidelines2, harnessing of all the available information when investigating hematological disorders into meaningful insights can be outdated, inaccurate, costly, and time-consuming. This ultimately risks limiting researchers’ productivity, thus ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Hereditary causes account for ∼10% of cancer cases, and an estimated 20% of cancer patients have a family history of cancer. Identification of an individual with a suspected hereditable cancer can lead to additional examinations and help formulate the most appropriate prevention strategies. Evaluating the predisposition to develop inherited cancer depends on the ability to characterize genes ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Maximize your biologically actionable insights from small tumor samples with the SOPHiA DDM™ RNAtarget Technology end-to-end solutions. Gene fusions have been associated with various tumors and are recognized as valuable cancer biomarkers in cancer research1. Targeted RNA sequencing is recommended to maximize novel fusion detection by identifying transcribed and potentially actionable ...
Manufactured by:Quantum Surgical SAS based inMontpellier, FRANCE
Epione is an open robotic solution compatible with any imaging systems. The medical robot is designed to allow physicians their choice of any ablative technologies (radiofrequency, microwave, cryoablation, irreversible electroporation) so they can decide the right therapy for each individual ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Powered by state-of-the-art proprietary algorithms, the SOPHiA DDMTM Platform reveals deep genomic insights from cell-free DNA, advancing your oncology research to new ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Rise above the noise to see what truly matters. Elevate your precision oncology program. Push the boundaries of your in-house liquid biopsy capabilities with MSK-ACCESS® powered with SOPHiA DDM™, a decentralized version of the rigorously validated cell-free DNA (cfDNA) assay developed and used in clinical routine by Memorial Sloan Kettering Cancer Center (MSK)1,2. ...
Manufactured by:Tempus based inChicago, ILLINOIS (USA)
Open. Review. Confirm. Report. It's that easy. Automatic detection* of solid, part solid, and ground glass nodules. Our interactive workflow allows the user to add, edit, or delete detections with automatic updates to quantitative ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Next-generation sequencing (NGS) has the potential to revolutionize the diagnosis and treatment of cancers and rare diseases but creates extremely large, complex, and noisy datasets for analysis. Without the right analytical technology, pinpointing causative variants and obtaining actionable insights from NGS data requires specialist skills, multiple resources, and considerable time. The ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Clinical interpretation has been one of the most complex and time-consuming aspects of transforming genomic data into meaningful results, until ...
by:Intrasense based inMontpellier, FRANCE
An advanced, fully orchestrated visualization solution. ...
by:SOPHiA Genetics based inBoston, MASSACHUSETTS (USA)
Deeper genomic insights, fewer missed opportunities. CGP enables clinical researchers to identify actionable variants and biomarkers across hundreds of genes using a single solution. The SOPHiA DDMTM Platform offers decentralized, in-house next generation sequencing (NGS) applications that help maximize insights from CGP data by leveraging advanced analytical capabilities, intutive interpretation ...